Ultrasound-triggered and glycosylation inhibition-enhanced tumor piezocatalytic immunotherapy.
Glycosylation
Animals
Immunotherapy
/ methods
Mice
Deoxyglucose
/ pharmacology
Cell Line, Tumor
Reactive Oxygen Species
/ metabolism
Catalysis
Tumor Microenvironment
/ immunology
Bismuth
/ chemistry
Female
Humans
Ferric Compounds
/ chemistry
Polysaccharides
/ chemistry
Ultrasonic Waves
Neoplasms
/ therapy
Mice, Inbred BALB C
Lung Neoplasms
/ immunology
Mice, Inbred C57BL
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
18 Oct 2024
18 Oct 2024
Historique:
received:
12
09
2023
accepted:
10
10
2024
medline:
19
10
2024
pubmed:
19
10
2024
entrez:
18
10
2024
Statut:
epublish
Résumé
Nanocatalytic immunotherapy holds excellent potential for future cancer therapy due to its rapid activation of the immune system to attack tumor cells. However, a high level of N-glycosylation can protect tumor cells, compromising the anticancer immunity of nanocatalytic immunotherapy. Here, we show a 2-deoxyglucose (2-DG) and bismuth ferrite co-loaded gel (DBG) scaffold for enhanced cancer piezocatalytic immunotherapy. After the implantation in the tumor, DBG generates both reactive oxygen species (ROS) and piezoelectric signals when excited with ultrasound irradiation, significantly promoting the activation of anticancer immunity. Meanwhile, 2-DG released from ROS-sensitive DBG disrupts the N-glycans synthesis, further overcoming the immunosuppressive microenvironment of tumors. The synergy effects of ultrasound-triggered and glycosylation inhibition enhanced tumor piezocatalytic immunotherapy are demonstrated on four mouse cancer models. A "hot" tumor-immunity niche is produced to inhibit tumor progress and lung metastasis and elicit strong immune memory effects. This work provides a promising piezocatalytic immunotherapy for malignant solid tumors featuring both low immunogenicity and high levels of N-glycosylation.
Identifiants
pubmed: 39424801
doi: 10.1038/s41467-024-53392-1
pii: 10.1038/s41467-024-53392-1
doi:
Substances chimiques
Deoxyglucose
9G2MP84A8W
Reactive Oxygen Species
0
Bismuth
U015TT5I8H
Ferric Compounds
0
Polysaccharides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9023Informations de copyright
© 2024. The Author(s).
Références
Zhu, P. et al. MnOOH-catalyzed autoxidation of glutathione for reactive oxygen species production and nanocatalytic tumor innate immunotherapy. J. Am. Chem. Soc. 145, 5803–5815 (2023).
pubmed: 36848658
doi: 10.1021/jacs.2c12942
Wu, W. et al. Bacterial metabolism-initiated nanocatalytic tumor immunotherapy. Nanomicro Lett. 14, 220 (2022).
pubmed: 36367591
pmcid: 9652197
Wu, W. et al. Photoactivatable immunostimulatory nanomedicine for immunometabolic cancer therapy. J. Am. Chem. Soc. 144, 19038–19050 (2022).
pubmed: 36215038
doi: 10.1021/jacs.2c07872
Del Paggio, J. C. Cancer immunotherapy and the value of cure. Nat. Rev. Clin. Oncol. 15, 268–270 (2018).
pubmed: 29459643
doi: 10.1038/nrclinonc.2018.27
Ding, Y., Wang, Y. & Hu, Q. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. Exploration 2, 20210106 (2022).
pubmed: 37323702
pmcid: 10190958
doi: 10.1002/EXP.20210106
Cheng, F. et al. Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of large tumors with abscopal effect. Sci. Adv. 9, eade6257 (2023).
pubmed: 37450588
pmcid: 10348685
doi: 10.1126/sciadv.ade6257
Wang, F. et al. Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. Sci. Adv. 6, eaaz8985 (2020).
pubmed: 32490201
pmcid: 7239700
doi: 10.1126/sciadv.aaz8985
Colen, R. R. et al. Radiomic signatures to predict response to targeted therapy and immune checkpoint blockade in melanoma patients (pts) on neoadjuvant therapy. J. Clin. Oncol. 38, 10067–10067 (2020).
doi: 10.1200/JCO.2020.38.15_suppl.10067
Ma, L. et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell 186, 3148–3165.e20 (2023).
pubmed: 37413990
pmcid: 10372881
doi: 10.1016/j.cell.2023.06.002
Mugarza, E. et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci. Adv. 8, eabm8780 (2022).
pubmed: 35857848
pmcid: 9299537
doi: 10.1126/sciadv.abm8780
Chen, Z. et al. Peptide-appended nanosonosensitizers targeting tumor glycolysis for synergistic sonodynamic-immunometabolic therapy of spinal-metastasized tumor. Adv. Mater. 35, 2304246 (2023).
doi: 10.1002/adma.202304246
Pu, Y. et al. Starvation therapy enabled “switch-on” NIR-II photothermal nanoagent for synergistic in situ photothermal immunotherapy. Nano Today 44, 101461 (2022).
doi: 10.1016/j.nantod.2022.101461
Wu, W., Pu, Y. & Shi, J. Nanomedicine-enabled chemotherapy-based synergetic cancer treatments. J. Nanobiotechnology 20, 4 (2022).
pubmed: 34983555
pmcid: 8725296
doi: 10.1186/s12951-021-01181-z
Kuai, R. et al. Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. Sci. Adv. 4, eaao1736 (2018).
pubmed: 29675465
pmcid: 5906077
doi: 10.1126/sciadv.aao1736
Zhu, P., Chen, Y. & Shi, J. Piezocatalytic tumor therapy by ultrasound-triggered and BaTiO
doi: 10.1002/adma.202001976
Truong Hoang, Q. et al. Piezocatalytic 2D WS
doi: 10.1002/adma.202300437
Chen, S. et al. Piezocatalytic medicine: an emerging frontier using piezoelectric materials for biomedical applications. Adv. Mater. 35, 2208256 (2023).
doi: 10.1002/adma.202208256
Zheng, R.-R. et al. Paraptosis inducer to effectively trigger immunogenic cell death for metastatic tumor immunotherapy with IDO inhibition. ACS Nano 17, 9972–9986 (2023).
pubmed: 37200049
doi: 10.1021/acsnano.2c11964
Yu, J. et al. Design of a self-driven probiotic-CRISPR/Cas9 nanosystem for sono-immunometabolic cancer therapy. Nat. Commun. 13, 7903 (2022).
pubmed: 36550159
pmcid: 9780327
doi: 10.1038/s41467-022-35580-z
Lee, Y. et al. Hyaluronic acid-bilirubin nanomedicine-based combination chemoimmunotherapy. Nat. Commun. 14, 4771 (2023).
pubmed: 37553327
pmcid: 10409794
doi: 10.1038/s41467-023-40270-5
He, C., Jiang, Y., Guo, Y. & Wu, Z. Amplified ferroptosis and apoptosis facilitated by differentiation therapy efficiently suppress the progression of osteosarcoma. Small 19, 2302575 (2023).
doi: 10.1002/smll.202302575
Chao, Y. et al. Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. Sci. Adv. 6, eaaz4204 (2020).
pubmed: 32181368
pmcid: 7056299
doi: 10.1126/sciadv.aaz4204
Wu, W., Pu, Y., Yao, H., Lin, H. & Shi, J. Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity. Nano Today 42, 101377 (2022).
doi: 10.1016/j.nantod.2022.101377
Kong, Y. et al. Wireless localized electrical stimulation generated by an ultrasound-driven piezoelectric discharge regulates proinflammatory macrophage polarization. Adv. Sci. 8, 2100962 (2021).
doi: 10.1002/advs.202100962
Wu, W., Pu, Y. & Shi, J. Dual size/charge-switchable nanocatalytic medicine for deep tumor therapy. Adv. Sci. 8, 2002816 (2021).
doi: 10.1002/advs.202002816
Wu, W. et al. Enhanced tumor-specific disulfiram chemotherapy by in situ Cu
pubmed: 31251050
doi: 10.1021/jacs.9b03503
Ou, W. et al. In-situ cryo-immune engineering of tumor microenvironment with cold-responsive nanotechnology for cancer immunotherapy. Nat. Commun. 14, 392 (2023).
pubmed: 36693842
pmcid: 9873931
doi: 10.1038/s41467-023-36045-7
Mohme, M., Riethdorf, S. & Pantel, K. Circulating and disseminated tumour cells-mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017).
pubmed: 27644321
doi: 10.1038/nrclinonc.2016.144
Greco, B. et al. Disrupting N-glycan expression on tumor cells boosts chimeric antigen receptor T cell efficacy against solid malignancies. Sci. Transl. Med. 14, eabg3072 (2022).
pubmed: 35044789
doi: 10.1126/scitranslmed.abg3072
Guo, H. B., Lee, I., Kamar, M., Akiyama, S. K. & Pierce, M. J. C. R. Aberrant N-glycosylation of β1 integrin causes reduced α5β1 integrin clustering and stimulates. Cell Migr. 62, 6837–6845 (2002).
Zhang, D. et al. 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 355, 176–183 (2014).
pubmed: 25218591
doi: 10.1016/j.canlet.2014.09.003
Lindström, M. et al. Lsm7 phase-separated condensates trigger stress granule formation. Nat. Commun. 13, 3701 (2022).
pubmed: 35764627
pmcid: 9240020
doi: 10.1038/s41467-022-31282-8
Yang, B., Chen, Y. & Shi, J. Tumor-specific chemotherapy by nanomedicine-enabled differential stress sensitization. Angew. Chem. Int. Ed. 59, 9693–9701 (2020).
doi: 10.1002/anie.202002306
Xu, M. L. et al. Piezo-photocatalytic synergy in BiFeO
pubmed: 36098495
doi: 10.1002/anie.202210700
Chu, Y. H. et al. Nanoscale domain control in multiferroic BiFeO
doi: 10.1002/adma.200601098
Zhu, C., Chen, Z., Zhong, C. & Lu, Z. Facile synthesis of BiFeO
doi: 10.1007/s10854-017-8437-6
Li, S. et al. Engineering ROS-responsive bioscaffolds for disrupting myeloid cell-driven immunosuppressive niche to enhance PD-L1 blockade-based postablative immunotherapy. Adv. Sci. 9, 2104619 (2022).
doi: 10.1002/advs.202104619
You, H. et al. Harvesting the vibration energy of BiFeO(
pubmed: 31225687
doi: 10.1002/anie.201906181
Wu, W., Pu, Y., Lin, H., Yao, H. & Shi, J. Starvation-sensitized and oxygenation-promoted tumor sonodynamic therapy by a cascade enzymatic approach. Research 2021, 9769867 (2021).
pubmed: 34195614
pmcid: 8214509
doi: 10.34133/2021/9769867
Pu, Y. et al. Sono-controllable and ROS-sensitive CRISPR-Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy. Adv. Mater. 33, 2104641 (2021).
doi: 10.1002/adma.202104641
Kurtoglu, M. et al. Under normoxia, 2-deoxy-d-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 6, 3049–3058 (2007).
pubmed: 18025288
doi: 10.1158/1535-7163.MCT-07-0310
Hayashi, K. et al. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat. Commun. 11, 6299 (2020).
pubmed: 33288764
pmcid: 7721802
doi: 10.1038/s41467-020-19970-9
Krysko, D. V. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat. Rev. Cancer 12, 860–875 (2012).
pubmed: 23151605
doi: 10.1038/nrc3380
Ma, H. et al. ER-targeting cyanine dye as an NIR photoinducer to efficiently trigger photoimmunogenic cancer cell death. J. Am. Chem. Soc. 144, 3477–3486 (2022).
pubmed: 35076232
doi: 10.1021/jacs.1c11886
Liang, J.-L. et al. Immunostimulant hydrogel-guided tumor microenvironment reprogramming to efficiently potentiate macrophage-mediated cellular phagocytosis for systemic cancer immunotherapy. ACS Nano 17, 17217–17232 (2023).
pubmed: 37584451
doi: 10.1021/acsnano.3c05093
Chen, M. et al. Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy. Biomaterials 303, 0142–9612 (2023).
doi: 10.1016/j.biomaterials.2023.122386
Chen, X. S., Moon, J. J. & Cheon, J. New opportunities in cancer immunotherapy and theranostics. Acc. Chem. Res. 53, 2763–2764 (2020).
pubmed: 33317270
doi: 10.1021/acs.accounts.0c00724
Munn, L. L. & Jain, R. K. Vascular regulation of antitumor immunity. Science 365, 544–545 (2019).
pubmed: 31395771
pmcid: 7321824
doi: 10.1126/science.aaw7875
Meng, Q., Ding, B., Ma, P. A. & Lin, J. Interrelation between programmed cell death and immunogenic cell death: take antitumor nanodrug as an example. Small Methods 7, 2201406 (2023).
doi: 10.1002/smtd.202201406